Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II, Open Label, Single Dose Clinical Study to Evaluate the Safety and Therapeutic Effects of Transplantation of MNV-BM-BLD (Autologous cd34+ Cells Enriched With Blood Derived Mitochondria) in Pediatric Patients With Pearson Syndrome

Next Previous
X
Search
Trial Profile

A Phase I/II, Open Label, Single Dose Clinical Study to Evaluate the Safety and Therapeutic Effects of Transplantation of MNV-BM-BLD (Autologous cd34+ Cells Enriched With Blood Derived Mitochondria) in Pediatric Patients With Pearson Syndrome

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 06 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MNV-BLD (Primary)
  • Indications VLCAD deficiency
  • Focus Adverse reactions; Expanded access; Therapeutic Use
  • Sponsors Minovia Therapeutics

    • Most Recent Events

    • 01 Oct 2021 According to a Minovia therapeutics media release, Toren, of the division of pediatric hematology and oncology, is lead Principal Investigator of this study.
    • 30 Aug 2021 Status changed from recruiting to completed.
    • 12 Mar 2021 According to a Minovia therapeutics media release, twelve patients have been dosed so far in Israel in this study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top